|
Trial
|
Patient
|
TAG-72 post heat extraction (fold increase)
|
Anti-idiotype titer
|
|---|
|
1:100
|
1:1000
|
|---|
|
C-9701
|
101 F
|
8.1
|
++
|
++
|
| |
201A
|
>2.6
|
+++
|
+++
|
| |
202B
|
1.8
|
+++
|
+++
|
| |
206 K
|
2.5
|
+
|
+
|
| |
105 J
|
1.2
|
+
|
++
|
| |
106 M
|
2.5
|
+
|
+
|
| |
204D
|
UND
|
-
|
-
|
| |
102G
|
>1.8
|
+++
|
++
|
| |
205E
|
>1.0
|
++
|
++
|
|
C-9702
|
301B
|
1.3
|
+
|
++
|
| |
303D
|
>1.4
|
+
|
++
|
| |
401A
|
NA
|
+
|
-
|
-
NA, data not available, UND TAG-72 undetectable.
- +, 1.5- to 3-fold increase; ++, 3.1- to 5-fold increase; +++, > 5-fold increase
- TAG-72 was detected in sera samples from IV-infused (trial C-9701) and intra-HA-infused (trial C-9702) CART72 cell patients following heat extraction of the TAG-72 to dissociate the antigen from inhibitory antibodies. Antibodies against the CC49 antibody were detected in all evaluable patients following infusion with CART72 cells comparing the RIA titer post-infusion versus pre-infusion. The detection of anti-CC49 antibodies coincided with the clearance of CART72 cells as measured by PCR
